News | May 30, 2007

D.C. Declares June 3 the Official “Molecular Imaging Week”

May 31, 2007 - The week of June 3 has been declared “Molecular Imaging Week,” which coincides with SNM’s 54th Annual Meeting. In addition, the District of Columbia issued a “letter of welcome” to SNM for holding the world’s largest event for molecular imaging and nuclear medicine professionals in the city.

In a statement in the Congressional Record, Rep. James P. Moran (D-VA-8th) said, “Molecular imaging and therapy procedures provide safe, painless and cost-effective techniques to image the body and treat disease. These procedures are crucial in the early diagnosis of cancer, renal disease, cardiac disease and Alzheimer’s. Imaging procedures often identify abnormalities very early in the progress of a disease—long before many medical problems are apparent with other diagnostic tests. The techniques that are used in molecular imaging include radiotracer imaging/nuclear medicine, magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), optical imaging, the PET scan, ultrasound and others.” Moran urged his colleagues “to join me in supporting policies that will continue to keep our nation on the cutting edge of molecular imaging research.”

He says further, “Molecular imaging offers unique insights that allow a more targeted approach to evaluation and management of heart disease. It also plays a pivotal role in guiding the management of cancer: diagnosis, staging (extent and location), assessing therapeutic targets, monitoring therapy and evaluating prognosis, and is playing an increasingly significant role in conditions such as tumors, dementias (Alzheimer’s and others), movement disorders, seizures disorders and psychiatric disorders.”

In addition, “Molecular imaging delivers on the promise of ‘personalized medicine’—it can provide patient-specific information that allows tailored treatment of disease. It can show a precise (molecular) level of detail that provides new information for diagnosis. It is also key to the development of pharmaceuticals and genetic therapy. Molecular therapy can target molecules that deliver the therapeutic agent directly to the site of interest, bypassing normal tissue and avoiding the toxic side effects of many current therapies.”

The Virginia representative said that more than 4,000 individuals would be attending “the world’s largest event focused exclusively on the fields of nuclear medicine and molecular imaging.” The congressman noted that more than 20 million people require molecular/nuclear medicine procedures each year. These procedures include PET scans to diagnose and monitor treatment of cancer, diagnose neurological disease such as Alzheimer’s and stroke, cardiac stress tests, bone scans and follow-up for breast and prostate cancer patients and lung scans for blood clots.

Moran noted that SNM created the Molecular Imaging Center of Excellence, an organizational component of the society that is dedicated to all aspects of molecular imaging in the detection and management of disease.

District of Columbia Mayor Adrian M. Fenty noted that “more than 4,000 physicians, scientists, physicists and pharmacists will attend this meeting to discuss issues of concern to revolutionize modern medicine for patients through the use of molecular imaging and therapy.” He added, “SNM, the leading professional association for molecular and nuclear imaging and therapy, has 16,000 members across the world who are dedicated to improving patient care.”

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Overlay Init